Presented at the 127th ASCPT International Meeting, March 2026
Katie Owens, Jingjing Yu, Chris Kinsella, Sophie Argon, and Isabelle Ragueneau-Majlessi
Abstract
A systematic evidence-based approach leveraging regulatory approved characterizations per the ICH M12 Guideline for Drug Interaction Studies and clinical DDI and/or pharmacogenetic data can be used to generate dynamic lists of potential concomitant medications for use in a particular clinical trial.